<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078818</url>
  </required_header>
  <id_info>
    <org_study_id>Tratamiento con hierro/2007</org_study_id>
    <nct_id>NCT01078818</nct_id>
  </id_info>
  <brief_title>Oral and Intravenous Iron in Patients Postoperative Cardiovascular Surgery Under Extracorporeal Circulation</brief_title>
  <official_title>A Phase IV, Unicenter, Randomized, Double-Blind, Parallel-Group, Comparaty Study of Intravenous and Oral Iron vs Placebo in Patient Under Extracorporeal Circulation in Cardiovascular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Canaria Rafael Clavijo para la Investigación Biomédica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Canaria Rafael Clavijo para la Investigación Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anaemia is a common postoperative problem of cardiovascular surgery after cardiopulmonary
      bypass (CPB). Because of this the need for hemoderived blood transfusions is high. The
      purpose of this study was to compare the clinical efficacy of intravenous and oral iron in
      anaemia and the impact of the iron on the transfusion rate in postoperative cardiovascular
      surgery under extracorporeal circulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective double dummy triple blind study of 159 patients undergoing CPB; randomised in 3
      groups treated with iron intravenously (iv) (group I), with iron orally (group II) controlled
      with placebo (group III). Patients from group I were treated with iv Iron sucrose , three
      doses of 100 mg of iv iron every 24 hours during postoperative hospitalization and 1 pill/24
      h of oral placebo during the first month after discharge. Group II was programmed to receive
      1 iron pill orally every 24 hours pre and postoperatively and up to one month after discharge
      and a placebo while hospitalized. Group III was programmed to receive an oral and iv placebo
      pre and postoperatively.

      Variables were collected preoperatively, at operation room and at Intensive Care Unit
      admission and discharge, at postoperative floor discharge and at one month after surgical
      discharge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemoglobin and Hematocrit values</measure>
    <time_frame>2 years</time_frame>
    <description>The objective was to compare the clinical efficacy of intravenous and oral iron in anaemia and the impact on the transfusion rate needing in Cardiovascular surgery under cardiopulmonary bypass</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>need for hemoderived blood transfusions, postoperative stay and hospital costs</measure>
    <time_frame>2 years</time_frame>
    <description>The objective was to compare the clinical efficacy of intravenous and oral iron in anaemia and the impact on the transfusion rate needing in Cardiovascular surgery under cardiopulmonary bypass</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>IV trivalent saccharose hydroxide ferrous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral ferrous fumarate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral and intravenous Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV trivalent saccharose hydroxide ferrous</intervention_name>
    <description>Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up
1 month 1 oral placebo /24h</description>
    <arm_group_label>IV trivalent saccharose hydroxide ferrous</arm_group_label>
    <other_name>Venofer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral ferrous fumarate</intervention_name>
    <description>200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®)
Postoperative Period:
200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet</description>
    <arm_group_label>Oral ferrous fumarate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral and intravenous Placebo</intervention_name>
    <description>Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h</description>
    <arm_group_label>Oral and intravenous Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥ 18 years of age

          -  Patients subject to elective cardiac surgery under extracorporeal circulation

          -  Patients without previous anaemia, susceptible of treatment

          -  Patients without need of blood transfusion preoperative

          -  Patients providing written informed consent

          -  Patients who are able to complete all study visits per protocol

        Exclusion Criteria:

          -  Patients subject to elective cardiac surgery, but without extracorporeal circulation

          -  Patients who were treated with fibrinolytic therapy 48 hours before the surgery

          -  Patients with history of impaired renal function, (e.g., calculated creatinine
             clearance &lt;50 mL/min/1.73 m2)

          -  Patients operated of active endocarditis

          -  Redo-surgery patients

          -  Women who are pregnant or lactating

          -  Patients with clinical of digestive bleeding

          -  Patients with vitamin B12 deficit

          -  Patients with ferropenic anaemia

          -  Patients with clinical history of asthma or allergy

          -  Patients with active infection

          -  Patients who are included in another clinical study

          -  Patients with hepatic disease

          -  Patients with history of allergy to iron

          -  Patients unlikely to adhere to protocol follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pilar Garrido, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario de Canarias</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <state>Santa Cruz de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Reuler JB. Hypothermia: pathophysiology, clinical settings, and management. Ann Intern Med. 1978 Oct;89(4):519-27. Review.</citation>
    <PMID>358883</PMID>
  </reference>
  <reference>
    <citation>Huyzen RJ, van Oeveren W, Wei F, Stellingwerf P, Boonstra PW, Gu YJ. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass. Ann Thorac Surg. 1996 Aug;62(2):533-7.</citation>
    <PMID>8694618</PMID>
  </reference>
  <reference>
    <citation>Kirklin JW. Open-heart surgery at the Mayo Clinic. The 25th anniversary. Mayo Clin Proc. 1980 May;55(5):339-41.</citation>
    <PMID>6990115</PMID>
  </reference>
  <reference>
    <citation>Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med. 1981 Feb 26;304(9):497-503.</citation>
    <PMID>7453783</PMID>
  </reference>
  <reference>
    <citation>Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993 Feb;55(2):552-9. Review.</citation>
    <PMID>8431082</PMID>
  </reference>
  <reference>
    <citation>Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Aprotinin in cardiopulmonary bypass--effects on the Hageman factor (FXII)--Kallikrein system and blood loss. Blood Coagul Fibrinolysis. 1992 Feb;3(1):99-104.</citation>
    <PMID>1377956</PMID>
  </reference>
  <reference>
    <citation>Boyle EM Jr, Lille ST, Allaire E, Clowes AW, Verrier ED. Endothelial cell injury in cardiovascular surgery: atherosclerosis. Ann Thorac Surg. 1997 Mar;63(3):885-94. Review.</citation>
    <PMID>9066432</PMID>
  </reference>
  <reference>
    <citation>Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med. 1987 Jul 23;317(4):249-51.</citation>
    <PMID>3600716</PMID>
  </reference>
  <reference>
    <citation>Bracey AW, Radovancevic R, Riggs SA, Houston S, Cozart H, Vaughn WK, Radovancevic B, McAllister HA Jr, Cooley DA. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion. 1999 Oct;39(10):1070-7.</citation>
    <PMID>10532600</PMID>
  </reference>
  <reference>
    <citation>Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial. 2000 Nov-Dec;13(6):381-4. Review.</citation>
    <PMID>11130261</PMID>
  </reference>
  <reference>
    <citation>Rohling RG, Zimmermann AP, Breymann C. Intravenous versus oral iron supplementation for preoperative stimulation of hemoglobin synthesis using recombinant human erythropoietin. J Hematother Stem Cell Res. 2000 Aug;9(4):497-500.</citation>
    <PMID>10982248</PMID>
  </reference>
  <reference>
    <citation>Madi-Jebara SN, Sleilaty GS, Achouh PE, Yazigi AG, Haddad FA, Hayek GM, Antakly MC, Jebara VA. Postoperative intravenous iron used alone or in combination with low-dose erythropoietin is not effective for correction of anemia after cardiac surgery. J Cardiothorac Vasc Anesth. 2004 Feb;18(1):59-63.</citation>
    <PMID>14973801</PMID>
  </reference>
  <reference>
    <citation>Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood. 2000 Aug 1;96(3):823-33. Review.</citation>
    <PMID>10910892</PMID>
  </reference>
  <reference>
    <citation>Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999 Dec 23;341(26):1986-95. Review. Erratum in: N Engl J Med 2000 Feb 3;342(5):364.</citation>
    <PMID>10607817</PMID>
  </reference>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <last_update_submitted>March 2, 2010</last_update_submitted>
  <last_update_submitted_qc>March 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pilar Garrido Martin MD</name_title>
    <organization>Fundación Canaria Rafael Clavijo para la Investigación Biomédica</organization>
  </responsible_party>
  <keyword>Cardiac surgery</keyword>
  <keyword>Extracorporeal circulation</keyword>
  <keyword>Anaemia</keyword>
  <keyword>Intravenous iron</keyword>
  <keyword>Oral Iron</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferrous fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

